A practical reference on HGF/c-Met: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-27 and is reviewed periodically as new material appears.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
=== Battery electrolyte === Chitosan is being investigated as an electrolyte for rechargeable batteries with good performance and low environmental impact due to rapid biodegradability, leaving recycleable zinc. The electrolyte has excellent physical stability up to 50 °C, electrochemical stability up to 2 V with zinc electrodes, and accommodates redox reactions involved in the Zn-MnO2 alkaline system. As of 2022 results were promising, but the battery needed testing on a larger scale and under actual use conditions.
Supra, lock and key management systems Sicli, a supplier of fire extinguishers and hose reels in France and Switzerland Sensitech, a cold chain solutions provider based in the U.S. Taylor, a manufacturer of commercial foodservice equipment to service frozen desserts, beverages and grilled items UTEC, manufactures microprocessor-based controls for the HVAC and refrigeration industries
==== Veterinary vaccine ==== Recombinant Sendai virus (rSeV) vectors are currently being developed as a platform for the control and prevention of infectious diseases in animals. While vaccination is a cornerstone of ensuring animal health, food security, and economic stability, many existing veterinary vaccines rely on traditional inactivated or live attenuated formulations that may provide insufficient or short-lived protection. Recombinant SeV vectors offer several biological and practical advantages for addressing these challenges, especially for major pathogens like influenza A, foot-and-mouth disease (FMDV), and animal retroviruses as shown in the table below and described in the literature review.
Sources: en.wikipedia.org
==== Section C: Biology and Food Technology ==== The activities of Section C deal with the application of refrigeration technologies to life sciences and food sciences. Commission C1 Cryobiology, cryomedicine and health products is particularly focused on the application of refrigeration technologies on various branches of medicine: cryosurgery and oncology, cryotherapy, blood, organs and tissue preservation, health products (especially vaccines and thermosensitive preparations). On the one hand, the work focuses on the biological and biochemical aspects of the effects of refrigeration on organs, tissues and treated products, and on the other hand, on the applied refrigeration techniques and technologies. Commission C2 food science and engineering is focused more particularly on the application of refrigeration technologies in the area of food sciences: preservation (refrigeration, freezing); hygiene and safety in its microbiological aspect; process (lyophilisation, cryoconcentration, cryoprecipitation, partial or total crystallisation). The work focuses on establishing a model for the transfer of heat and matter during refrigeration treatments, on the effects of refrigeration on food products, and on the evolution kinetics of products kept in cold storage. The work deals with the impact of the integrity of the cold chain on the quality of food, including in warm climate countries.
=== Lightweight === Backpackers must carry everything with them so they require all of their gear and food to be as lightweight as possible. Campers often turn to freeze-dried and dehydrated meals and ingredients for this reason, but they will also sometimes take a pouch of tuna or some other ingredient with a high water content with them as a treat, providing that the item has nutritional value. Backpackers usually take empty containers back with them for recycling and proper disposal.
Tulips are mainly distributed along a band corresponding to latitude 40° north, from southeast of Europe (Greece, Albania, North Macedonia, Kosovo, Southern Serbia, Bulgaria, most part of Romania, Ukraine, Russia) and Turkey in the west, through the Levant (Syria, Israel, Palestinian Territories, Lebanon and Jordan) and the Sinai Peninsula. From there it extends eastwards through Jerevan (Armenia), and Baku (Azerbaijan) and on the eastern shore of the Caspian Sea through Turkmenistan, Bukhara, Samarkand and Tashkent (Uzbekistan), to the eastern end of the range in the Pamir-Alai and Tien-Shan mountains in Central Asia, which form the centre of diversity. Further to the east, Tulipa is found in the western Himalayas, southern Siberia, Inner Mongolia, and as far as the northwest of China. While authorities have stated that no tulips west of the Balkans are native, subsequent identification of Tulipa sylvestris subsp. australis as a native of the Iberian Peninsula and adjacent North Africa shows that this may be a simplification. In addition to these regions in the west tulips have been identified in Greece, Cyprus and the Balkans. In the south, Iran marks its furthest extent, while the northern limit is Ukraine. Although tulips are also found throughout most of the Mediterranean and Europe, these regions do not form part of the natural distribution. Tulips were brought to Europe by travellers and merchants from Anatolia and Central Asia for cultivation, from where they escaped and naturalised (see map).
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.